publication venue for
- Time to ACT-UP: Update on precautionary allergen labelling (PAL).. 17:100972. 2024
- World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) guideline update - XI - Milk supplement/replacement formulas for infants and toddlers with CMA - Systematic review.. 17:100947. 2024
- World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) guidelines update – XVI - Nutritional management of cow's milk allergy. 17:100931-100931. 2024
- World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) guideline update – XII – Recommendations on milk formula supplements with and without probiotics for infants and toddlers with CMA. 17:100888-100888. 2024
- World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) guidelines update – X – Breastfeeding a baby with cow's milk allergy. 16:100830-100830. 2023
- World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) Guideline update – VII – Milk elimination and reintroduction in the diagnostic process of cow's milk allergy. 16:100785-100785. 2023
- A systematic review of quality and consistency of clinical practice guidelines on the primary prevention of food allergy and atopic dermatitis. 16:100770-100770. 2023
- Managing food allergy: GA2LEN guideline 2022. 15:100687-100687. 2022
- Quality and consistency of clinical practice guidelines on the prevention of food allergy and atopic dermatitis: Systematic review protocol. 15:100679-100679. 2022
- World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) Guidelines update - III - Cow's milk allergens and mechanisms triggering immune activation. 15:100668-100668. 2022
- World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) guideline update – XIII – Oral immunotherapy for CMA – Systematic review. 15:100682-100682. 2022
- World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow’s Milk Allergy (DRACMA) Guideline update – XIV – Recommendations on CMA immunotherapy. 15:100646-100646. 2022
- World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow’s Milk Allergy (DRACMA) Guidelines update – VI – A quality appraisal with the AGREE II instrument. 15:100613-100613. 2022
- World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) Guidelines update – I – Plan and definitions. 15:100609-100609. 2022
- Oral immunotherapy for peanut allergy: a systematic review and meta-analysis. 13:100416-100416. 2020
- The global impact of the DRACMA guidelines cow’s milk allergy clinical practice. 11:2-2. 2018
- Erratum to: Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement. 10:6-6. 2017
- A clinical reading on “World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Probiotics”. 9:9-9. 2016
- Insights, attitudes, and perceptions about asthma and its treatment: a multinational survey of patients from Europe and Canada. 9:13-13. 2016
- Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement. 9:33-33. 2016
- Therapeutic interventions in severe asthma. 9:40-40. 2016
- World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Prebiotics. 9:10-10. 2016
- World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Vitamin D. 9:17-17. 2016
- Allergen immunotherapy on the way to product-based evaluation—a WAO statement. 8:29-29. 2015
- World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Probiotics. 8:4-4. 2015
- Anti-IL5 therapy for asthma and beyond. 7:32-32. 2014
- Immunotherapy – 2067. FEL d 1 peptide antigen desensitization safety and efficacy in a double-blind, placebo-controlled environmental exposure chamber study. 6:P150-P150. 2013
- Immunotherapy – 2080. Fel d 1 derived peptide antigen desensitization results in a persistent treatment effect on symptoms of cat allergy 1 year after 4 doses. 6:P162-P162. 2013
- Mechanisims of asthma and allergic disease – 1085. Safety and tolerability of escalating doses of house dust mite peptide antigen desensitisation. 6:P81-P81. 2013
- 246 Assessment of the Quality of Methodological Rigour and Reporting of Clinical Practice Guidelines for the Management of Allergic Rhinitis—Qugar Study. 5:S80-S81. 2012
- 246 Assessment of the Quality of Methodological Rigour and Reporting of Clinical Practice Guidelines for the Management of Allergic Rhinitis—Qugar Study. 5:S97-S98. 2012
- World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) Guidelines. 3:57-161. 2010